We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Early Clues to Diabetic Kidney Disease

By HospiMedica staff writers
Posted on 31 Mar 2008
A new study has found that for patients with type I diabetes, increased levels of uric acid in the blood may be an early sign of diabetic kidney disease, appearing before any significant change in urine albumin level, the standard screening test.

Researchers at the Joslin Diabetes Center (Boston, MA, USA) measured serum uric acid concentration in 675 patients with type I diabetes. More...
A medical history and measurements of blood pressure (BP), hemoglobin A1c, albumin excretion rate, and serum concentrations of uric acid and cystatin C were obtained; estimated glomerular filtration rate (GFR) was measured by a cystatin C-based formula.

On screening tests, results showed 311 patients had small amounts of the protein albumin--called microalbuminuria--in the urine. The other 364 patients had normal urine albumin levels. None of the patients had even higher levels of albumin (albuminuria), representing more advanced diabetic nephropathy; in contrast, the serum uric acid level was consistently related to kidney function--the higher the uric acid, the lower the kidney function--and one in five had some impairment of kidney function on a standard GFR test. In univariate and multivariate analyses, lower GFR was strongly and independently associated with higher serum uric acid and higher urinary albumin excretion rate, older age, and antihypertensive treatment. The study was published online ahead of print on February 13, 2008, in the Clinical Journal of the American Society of Nephrology.

"The serum uric acid concentration is modifiable by drugs or by decreasing the intake of dietary protein, the main source of uric acid,” said lead author Elizabeth Rosolowsky, M.D. "If follow-up studies, already underway, demonstrate that serum uric acid concentration predicts the course of early decline in kidney function, then clinical trials would be justified to test whether modifying serum uric acid concentration also modifies the course of renal function decline in type I diabetic patients with high normoalbuminuria or microalbuminuria.”

The association between high serum uric acid and insulin resistance has been known since the early part of the 20th century. Nevertheless, recognition of high serum uric acid as a risk factor for diabetes has been a matter of debate. In fact, hyperuricemia has always been presumed to be a consequence of insulin resistance rather than its precursor. On the other hand, it has been shown that high serum uric acid is associated with higher risk of type II diabetes independent of obesity, dyslipidemia, and hypertension.


Related Links:
Joslin Diabetes Center

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.